No Prescription |
 |
 | ||
|
Chlorvescent B |
|
| ||
No Prescription » Prescription Drugs 4 » Chlorvescent B This medication is a mineral supplement used to prevent or treat low amounts of potassium in the blood. A normal level of potassium in the blood is important so that your cells nerves heart muscles and kidneys work properly. Normal blood levels of potassium are usually achieved by eating a well-balanced diet. However certain situations cause your body to lose potassium faster than you can replace it from your diet. These situations include treatment with certain "water pills" (diuretics) a poor diet or certain medical conditions (e.g. severe diarrhea especially with vomiting).Indications:Treatment of potassium deficiency (particularly hypochloremic or hypokalemic alkalosis) associated with diuretic and steroid therapy vomiting and diarrhoea ulcerative colitis steatorrhoea diabetes insipidus and uncontrolled diabetes mellitus ileostomy or colostomy patients cirrhosis and dietary insufficiency.Dosage and Administration:1 tablet in half a glass full of water per day is normally sufficient to correct potassium and chloride deficiencies. In more severe depletion up to 4 tablets (56 mmol potassium and 32 mmol chloride) can be taken daily in divided doses in water. Buy Chlorvescent B and other Prescription Drugs 4 products online at Medstore. Buy Online at Medstore - Click Here!
About Chlorvescent B: Product Type: Prescription Drugs 4 Chlorvescent B/CRRNT (Generic Potassium Chloride ) Chlorvescent B/CRRNT (Generic Potassium Chloride) Generic Potassium Chloride 548mg/298mg 60 Tablets 120(2 x 60) Tablets Generic Potassium Chloride Chlorvescent B/CRRNT
View more Prescription Drugs 4 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
